期刊文献+

紫杉醇纳米制剂研究进展 被引量:1

PROGRESSION OF NANOPARTICLE FORMULATION FOR PACLITAXEL
下载PDF
导出
摘要 紫杉醇在肺癌、胸腺癌、食道癌、淋巴瘤等多种肿瘤的治疗中得到广泛应用。但紫杉醇水溶性差,传统制剂采用聚氧乙烯蓖麻油(Cremophor EL)与无水乙醇(1∶1)为增溶溶媒,临床使用中引起的不良反应较多。为提高紫杉醇制剂的治疗效果,降低不良反应,国内外学者致力于紫杉醇制剂学的研究。纳米制剂是现代药物制剂研究的前沿和热点,本文就紫杉醇纳米制剂的开发和应用进展进行综述。 Paclitaxel is widely used in the treatment of lung cancer,breast cancer,esophageal cancer,lymphoma and other tumor. Clinical use of paclitaxel is limited by its poor aqueous solubility.Cremophor EL and ethanol( 1 ∶ 1) are used as solvent in traditional administration of paclitaxel.However,Cremophor EL has adverse reactions in clinic. Some alternative formulations have been studied to increase its therapeutic index and decrease toxicity and hypersensitivity. Nanoparticle formulation is the frontier and focus of modern pharmaceutical drug delivery system. In this paper,the latest development and application of paclitaxel nanoparticle formulations were reviewed.
出处 《内蒙古医科大学学报》 2014年第6期560-564,共5页 Journal of Inner Mongolia Medical University
基金 国家自然科学基金(81260615)
关键词 紫杉醇 纳米制剂 研究进展 paclitaxel nanoparticle drug delivery system progression
  • 相关文献

参考文献9

二级参考文献85

  • 1周卫,翁帼英,陈文忠,庄翌,傅晓阳,程光.紫杉醇脂质体在大鼠体内的组织分布[J].中国药学杂志,2005,40(18):1402-1404. 被引量:54
  • 2张珏,吕加国,朱驹.抗肿瘤药物紫杉醇的化学研究进展[J].中国新药杂志,2006,15(3):178-181. 被引量:13
  • 3仝新勇,周建平,谭燕,吴春勇,林文垚,刘馨.紫杉醇纳米脂质体在大鼠体内的药动学[J].中国医院药学杂志,2006,26(6):677-679. 被引量:10
  • 4Guo W,Johnson JL, Sumsullah K,et al. Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry:application to a pharmacokinetics study[ J ]. Anal Biochem, 2005,336 ( 2 ) : 213 - 220.
  • 5Michaud LB ,Valero V ,Hortobagyi G. Risk and benefits of taxanes in breast and ovarian cancer [ J ]. Drug Safety ,2000,23 (5) :401 - 428.
  • 6Biganzoli L, Licitra S, Moretti E, et ol. Taxanes in the elderly : Can we gain as much and be less toxic[J]? Crit Rev Oncol Hematol, 2009, 70(3) : 262-271.
  • 7Saloustros E, Mavroudis D, Georgoulias V. Paclitaxel and doeetaxel in the treatment of breast cancer[J]. Expert Opin Pharmacother, 2008, 9(15): 2603-2616.
  • 8Lee C, Gianos M, Klaustermeyer WB, et al. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents[J]. Ann Allergy, Asthma Immunol, 2009, 102(3): 179-187.
  • 9Miele E, Spinelli GP, Miele E, et al. Albumin-bound formulation of paclitaxel(Abraxane ABI-007) in the treatment of breast cancer[J]. Int J Nanomedicine, 2009, 4: 99-105.
  • 10Ruan G, Feng SS. Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid)(PLA-PEGPLA) microspheres for controlled release of pactitaxel[J]. Biomaterials, 2003, 24 (27) : 5037-5044.

共引文献53

同被引文献13

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部